Page last updated: 2024-11-12

echinocandin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

echinocandin B: a cyclic hexapeptide echinocandin antibiotic isolated from Aspergillus nidulans var. echinulatus with specific anti-yeast activity; inhibits beta-1,3-glucan synthesis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

echinocandin B : A cyclic hexapeptide echinocandin antibiotic isolated from Aspergillus nidulans var. echinulatus with specific anti-yeast activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID133562668
MeSH IDM0050856

Synonyms (1)

Synonym
echinocandin b

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"We used a straightforward pharmacodynamic approach based on a microdilution format and a colorimetric analysis to harmonize growth end points."( Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro.
Kontoyiannis, DP; Lewis, RE, 2005
)
0.33
"A microdilution-based pharmacodynamic method for testing antifungal combinations provides a less ambiguous description of the combined effects of antifungals against moulds and could be useful in reference laboratories that routinely evaluate the activity of antifungal combinations in vitro and in vivo."( Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro.
Kontoyiannis, DP; Lewis, RE, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
"We detected a fourfold decrease in the EC90 of voriconazole when tested in combination with micafungin (4 mg/L) against isolates of Aspergillus fumigatus and Aspergillus terreus, but not against an isolate of Aspergillus flavus."( Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro.
Kontoyiannis, DP; Lewis, RE, 2005
)
0.33

Bioavailability

ExcerptReferenceRelevance
" Owing to its poor oral bioavailability it can only be administered intravenously."( Anidulafungin: a new echinocandin for candidal infections.
de la Torre, P; Reboli, AC, 2007
)
0.34
" However, low oral bioavailability and solubility limit their application."( The synthesis and activity evaluation of N-acylated analogs of echinocandin B with improved solubility and lower toxicity.
Chen, M; Dong, Y; Feng, J; Ma, J; Ruan, S; Zhao, W; Zhu, B, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" This article provides an up-to-date review on the clinical pharmacology, indications, and dosage recommendations of approved and currently investigational therapeutics for treatment of invasive fungal infections in adult and pediatric patients."( Clinical pharmacology of antifungal compounds.
Gea-Banacloche, JC; Glasmacher, A; Groll, AH; Just-Nuebling, G; Maschmeyer, G; Walsh, TJ, 2003
)
0.32
" Dosing is once daily and drug interactions are few."( Echinocandin antifungal drugs.
Denning, DW, 2003
)
0.32
" This article reviews recent pertinent data with regard to dosing guidelines, efficacy, and toxicities of available systemic antifungal agents in the newborn."( Antifungal pharmacotherapy for neonatal candidiasis.
Bliss, JM; Gigliotti, F; Wellington, M, 2003
)
0.32
" These support the use of these drugs in neonates, but because of their largely noncomparative nature they can not define the optimal dosage or duration of therapy."( Antifungals in systemic neonatal candidiasis.
Aranda, JV; Frattarelli, DA; Giacoia, GP; Reed, MD, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (100)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (9.00)18.7374
1990's16 (16.00)18.2507
2000's43 (43.00)29.6817
2010's25 (25.00)24.3611
2020's7 (7.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.99%)5.53%
Reviews27 (26.73%)6.00%
Case Studies5 (4.95%)4.05%
Observational0 (0.00%)0.25%
Other68 (67.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]